BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12186341)

  • 21. Hormone replacement therapy use and the risk of stroke.
    Renoux C; Dell'aniello S; Garbe E; Suissa S
    Maturitas; 2008 Dec; 61(4):305-9. PubMed ID: 18996656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaginal polyps and hormones--is there a link? A case series.
    Sharma S; Albertazzi P; Richmond I
    Maturitas; 2006 Feb; 53(3):351-5. PubMed ID: 16029937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carcinoma of the endometrium in patients treated with tibolone.
    Yazigi R; Sahid S; Contreras L; Rodriguez T
    Gynecol Oncol; 2004 May; 93(2):568-70. PubMed ID: 15099984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormone replacement therapy use and variations in the risk of breast cancer.
    Opatrny L; Dell'Aniello S; Assouline S; Suissa S
    BJOG; 2008 Jan; 115(2):169-75; discussion 175. PubMed ID: 18081598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
    Hammar ML; van de Weijer P; Franke HR; Pornel B; von Mauw EM; Nijland EA;
    BJOG; 2007 Dec; 114(12):1522-9. PubMed ID: 17995496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Is the clinical profile of women treated with tibolone similar to that of women receiving a classical estrogen-progestogen therapy? Data from a nationwide survey in France].
    Jamin C; Bourg F; Legeai J; Senoussi S
    Gynecol Obstet Fertil; 2006 Mar; 34(3):224-32. PubMed ID: 16513401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tibolone: a unique version of hormone replacement therapy.
    Swegle JM; Kelly MW
    Ann Pharmacother; 2004 May; 38(5):874-81. PubMed ID: 15026563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Sexual dysfunction in the menopause. Incidence, pharmacological treatment and side effects].
    Gregersen N; Hilmand CB; Jensen PT; Giraldi AG
    Ugeskr Laeger; 2006 Feb; 168(6):559-63. PubMed ID: 16476214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hormone replacement therapy in women with past history of endometriosis.
    Soliman NF; Hillard TC
    Climacteric; 2006 Oct; 9(5):325-35. PubMed ID: 17000581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Relation between hormonal therapy and tibolone with SERMs in postmenopausal women's myomes growth].
    Carranza Lira S
    Ginecol Obstet Mex; 2008 Oct; 76(10):610-4. PubMed ID: 19062511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].
    Reginster JY
    J Gynecol Obstet Biol Reprod (Paris); 2002 Oct; 31(6):541-9. PubMed ID: 12407324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conjugated estrogen/progestagen versus tibolone hormone replacement therapy in postmenopausal women: Effects on carbohydrate metabolism and serum sex hormone-binding globulin.
    Odmark IS; Carlström K; Jonsson B; Jonasson AF
    Maturitas; 2006 Jan; 53(1):89-96. PubMed ID: 15964160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychological effects of tibolone and sequential estrogen-progestogen therapy in perimenopausal women.
    Inan I; Kelekci S; Yilmaz B
    Gynecol Endocrinol; 2005 Feb; 20(2):64-7. PubMed ID: 15823823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endometrial safety and bleeding with HRT: what's new?
    Sturdee DW
    Climacteric; 2007 Oct; 10 Suppl 2():66-70. PubMed ID: 17882676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women.
    Diaby V; Perreault S; Lachaine J
    Maturitas; 2007 Oct; 58(2):138-49. PubMed ID: 17870259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese postmenopausal women.
    Osmanağaoğlu MA; Osmanağaoğlu S; Osmanağaoğlu T; Okumuş B; Bozkaya H
    Fertil Steril; 2005 Aug; 84(2):384-93. PubMed ID: 16084879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does tibolone exacerbate atherosclerosis?
    Clarkson TB
    Eur Heart J; 2006 Mar; 27(6):635-7. PubMed ID: 16415302
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of hormone treatment on hemostasis variables.
    Kluft C
    Climacteric; 2007 Oct; 10 Suppl 2():32-7. PubMed ID: 17882670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study.
    Koh KK; Ahn JY; Jin DK; Yoon BK; Kim HS; Kim DS; Kang WC; Han SH; Choi IS; Shin EK
    Arterioscler Thromb Vasc Biol; 2003 Oct; 23(10):1889-94. PubMed ID: 12933531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.